LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

Search

ACADIA Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

22.13 2.31

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.28

Max

22.13

Schlüsselkennzahlen

By Trading Economics

Einkommen

-125M

19M

Verkäufe

-15M

244M

KGV

Branchendurchschnitt

16.277

51.748

EPS

0.11

Gewinnspanne

7.771

Angestellte

653

EBITDA

7.1M

19M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+32.34% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

443M

3.7B

Vorheriger Eröffnungskurs

19.82

Vorheriger Schlusskurs

22.13

Nachrichtenstimmung

By Acuity

50%

50%

142 / 381 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

ACADIA Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Juni 2025, 23:40 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium -- 2nd Update

15. Juni 2025, 23:27 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium -- Update

15. Juni 2025, 23:10 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium

13. Juni 2025, 22:33 UTC

Akquisitionen, Fusionen, Übernahmen

Millicom to Acquire Telefonica Ecuador for $380 Million

15. Juni 2025, 23:50 UTC

Market Talk

Gold Edges Higher Amid Likely Safe-Haven Demand -- Market Talk

15. Juni 2025, 23:47 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over Middle East -- Market Talk

15. Juni 2025, 23:41 UTC

Market Talk

Oil Rises Amid Middle East Tensions -- Market Talk

15. Juni 2025, 23:33 UTC

Market Talk

China Most Affected by Any Disruption to Iran Crude Oil Exports -- Market Talk

15. Juni 2025, 23:29 UTC

Market Talk

Oil Price Could Rise More This Week -- Market Talk

15. Juni 2025, 23:27 UTC

Market Talk

Fed's Powell Likely to Emphasize Ongoing Policy Patience -- Market Talk

15. Juni 2025, 23:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Juni 2025, 23:02 UTC

Market Talk

Global Energy Roundup: Market Talk

15. Juni 2025, 23:02 UTC

Market Talk

Rising Middle East Tensions Could Be Passing Storm for World Economy -- Market Talk

15. Juni 2025, 22:47 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Says Recommendation Requires Independent Expert Concluding Offer Is Fair, Reasonable

15. Juni 2025, 22:47 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Intends to Recommend Shareholders Vote In Favor of Transaction If Binding Offer Made

15. Juni 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Intends to Negotiate Terms of Process, Exclusivity Deed With XRG Consortium

15. Juni 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Santos to Give XRG Consortium Due Diligence Access

15. Juni 2025, 22:45 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Says XRG Consortium Offer Is Final, Had Made Two Earlier Proposals

15. Juni 2025, 22:45 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Says XRG Consortium Offering A$8.89/Share in Cash

15. Juni 2025, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Says XRG Consortium Includes Abu Dhabi Development Holding Co and Carlyle

15. Juni 2025, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Gets Takeover Offer From Consortium Led by Abu Dhabi's Adnoc

15. Juni 2025, 22:31 UTC

Market Talk

Gold Price Can Push Toward New All-Time High -- Market Talk

14. Juni 2025, 01:24 UTC

Akquisitionen, Fusionen, Übernahmen

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13. Juni 2025, 23:50 UTC

Akquisitionen, Fusionen, Übernahmen

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13. Juni 2025, 23:20 UTC

Akquisitionen, Fusionen, Übernahmen

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13. Juni 2025, 23:09 UTC

Akquisitionen, Fusionen, Übernahmen

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13. Juni 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13. Juni 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Millicom to Acquire Telefonica Ecuador for $380M

13. Juni 2025, 22:04 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Better Data Facilitate Investments In Oil Patch -- Market Talk

13. Juni 2025, 21:42 UTC

Akquisitionen, Fusionen, Übernahmen

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

Peer-Vergleich

Kursveränderung

ACADIA Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

32.34% Vorteil

12-Monats-Prognose

Durchschnitt 28.73 USD  32.34%

Hoch 37 USD

Tief 18 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ACADIA Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

14

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

14.845 / N/AUnterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

142 / 381 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.